Vanda Pharmaceuticals Files 8-K
Ticker: VNDA · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, financials
Related Tickers: VNDA
TL;DR
Vanda Pharma filed an 8-K on Oct 3rd for corporate changes and financials.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on October 3, 2024, reporting an amendment to its articles of incorporation or bylaws and financial statements/exhibits. The earliest event reported was October 2, 2024. The company is incorporated in Delaware and its principal executive offices are located in Washington, DC.
Why It Matters
This filing indicates corporate actions and the submission of financial documents, which are crucial for investors to understand the company's current status and compliance.
Risk Assessment
Risk Level: low — This is a routine filing for corporate actions and financial statements, not indicating immediate operational or financial distress.
Key Numbers
- 001-34186 — SEC File Number (Identifies the company's filing with the SEC.)
- 03-0491827 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- October 3, 2024 (date) — Filing date
- October 2, 2024 (date) — Earliest event reported date
- Delaware (jurisdiction) — State of incorporation
- Washington, DC (location) — Principal executive offices
FAQ
What specific amendments were made to Vanda Pharmaceuticals Inc.'s articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary text.
What type of financial statements and exhibits were filed?
The filing states that 'Financial Statements and Exhibits' were filed, but does not specify their nature or content.
What is the significance of the 'earliest event reported' date?
The earliest event reported date, October 2, 2024, signifies the date on which the events triggering this 8-K filing occurred.
Where are Vanda Pharmaceuticals Inc.'s principal executive offices located?
Vanda Pharmaceuticals Inc.'s principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
What is Vanda Pharmaceuticals Inc.'s fiscal year end?
Vanda Pharmaceuticals Inc.'s fiscal year ends on December 31st.
Filing Stats: 686 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2024-10-03 17:00:32
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma
Filing Documents
- d828148d8k.htm (8-K) — 32KB
- d828148dex31.htm (EX-3.1) — 158KB
- 0001193125-24-232306.txt ( ) — 388KB
- vnda-20241002.xsd (EX-101.SCH) — 4KB
- vnda-20241002_def.xml (EX-101.DEF) — 14KB
- vnda-20241002_lab.xml (EX-101.LAB) — 23KB
- vnda-20241002_pre.xml (EX-101.PRE) — 15KB
- d828148d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Bylaws of Vanda Pharmaceuticals Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 3, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary